Carmed Pharmaceuticals, a Turkey-based company specializing in standardized carvacrol-based formulations, announced plans to expand its U.S. distribution with an upcoming launch on OneLavi, a curated online marketplace for beauty, health, and wellness products. The move follows Carmed's previously announced plans to introduce its formulations on Amazon, reflecting a broader multi-channel approach to U.S. distribution.
Founded in 2019 after years of research, Carmed integrates traditional botanical knowledge with modern pharmaceutical methodology to develop standardized formulations designed to support immune resilience, cellular health, and overall physiological balance. The company's product portfolio includes Vacrol® Kids Spray, S-Mix®, Vacrol® Capsule, Vacrol-M® Capsule, and Omevaq-3®, all manufactured according to Good Manufacturing Practice (GMP) principles.
The addition of OneLavi to Carmed’s distribution strategy reflects the company’s focus on reaching consumers through curated platforms that emphasize quality, transparency, and product discovery. Unlike broader marketplaces, OneLavi provides a more selective environment where brands are positioned alongside premium wellness offerings. According to Newsworthy.ai, the launch is another step in Carmed’s U.S. expansion strategy, focused on increasing accessibility to its research-driven formulations while building long-term credibility in the American market.
“Expanding onto OneLavi allows us to introduce our formulations in a curated environment where quality and product integrity are prioritized,” said Mustafa Can, Founder of Carmed Pharmaceuticals. “This aligns with our commitment to standardized development and consistent formulation quality.”
As part of its OneLavi launch, Carmed plans to introduce several core formulations. Vacrol® Kids Spray is a carvacrol-based spray formulated to support upper respiratory wellness and microbial balance for children ages 4-11. S-Mix® is a synergy-driven formulation designed to support immune function and healthy cellular activity. Vacrol® Capsule is a standardized carvacrol formulation developed to support microbial balance and immune resilience. Vacrol-M® Capsule is a multi-component botanical formulation designed to support immune function and respiratory wellness. Omevaq-3® is a targeted formulation developed to support cellular energy metabolism and cognitive wellness. Vacrol® Kids Spray and S-Mix® are gluten-free, non-GMO, sugar-free, preservative-free, and halal-certified.
Carmed’s formulation approach is supported by ongoing collaboration with academic institutions, laboratories, and medical researchers focused on bioactive compounds and formulation science. In January 2026, a study published in the peer-reviewed journal Plants examined Vacrol® and S-Mix® in preclinical laboratory and in ovo models, contributing to the broader scientific investigation of carvacrol-based formulations and multicomponent botanical interactions. The company emphasizes that this research reflects scientific investigation into formulation science and is not presented as evidence that its consumer products diagnose, treat, cure, or prevent any disease.
“The OneLavi launch is an important step in building awareness and accessibility for Carmed in the United States,” said Ceren Can, Global Brand Director of Carmed Pharmaceuticals. “We are focused on introducing our formulations to new audiences while maintaining the same standards of quality, consistency, and research-driven development.”
Availability timelines and product listings on OneLavi will be announced in the coming weeks. Carmed Pharmaceuticals invites consumers to visit its website for more information.
